Skip to content

Ellie Steiner focuses her litigation practice on intellectual property, with an emphasis on patent litigation and client counseling in the pharmaceutical, biologic, and medical device industries. Ellie has represented clients in a wide range of other patent and general commercial matters, including software, semiconductor processing, and the Internet, in federal courts throughout the United States and before the International Trade Commission. She has also litigated a number of trademark and copyright cases.

Ellie has experience with Hatch-Waxman and BPCIA litigations and has obtained favorable judgments and settlements in district court and inter partes review proceedings. In addition to litigation, Ellie counsels clients on a wide range of intellectual property licensing issues, including drafting and negotiating patent licenses. She also counsels clients regarding patent validity and infringement in anticipation of product development. Ellie frequently works with clients to create strategies based on her extensive knowledge of the regulatory landscape coupled with a strategic approach to litigation.


J.D., Duke University School of Law, Durham, North Carolina
B.S., University of California-San Diego, La Jolla, California, Molecular Biology


Daily Journal’s Top Intellectual Property Lawyer, 2024

Recognized as one of the best performing ANDA attorneys representing defendants in Patexia’s 2023 ANDA Litigation Intelligence Report

State Bar Licenses

California, New York

Court Admissions

U.S. Supreme Court
U.S. Court of Appeals, Federal Circuit
U.S. District Ct., N.D. of California
U.S. District Ct., E.D. of California
U.S. District Ct., C.D. of California
U.S. District Ct., S.D. of California
U.S. District Ct., S.D. of New York
U.S. District Ct., E.D. of New York
  • Secured Federal Circuit victories for Viatris (formerly Mylan) on appeals affirming PTAB decisions invalidating several Sanofi patents related to Sanofi’s Lantus and Lantus SoloSTAR insulin glargine products, paving the way for Viatris to commercialize Semglee, the first approved interchangeable biologic.
  • Secured trial verdict of non-infringement and invalidity in favor of Viatris (formerly Mylan) on Sanofi’s patent for an injector pen for delivering insulin.
  • Secured a victory for Viatris (formerly Mylan) in IPR proceedings at the PTAB, clearing a significant hurdle towards the marketing of Viatris’ proposed 2.5 mg rivaroxaban tablets.
  • Represented Mylan Pharmaceuticals in breach of contract and patent infringement dispute arising from Mylan’s launch of its generic colchicine product.
  • Successfully served as counsel for generic pharmaceutical companies in Hatch-Waxman Act litigation relating to the following pharmaceutical products: Uptravi (selexipag), Xarelto (rivaroxaban), Pomalyst (pomalidomide), Revlimid (lenalidomide), Suboxone (buprenorphine/naloxone sublingual film), Pradaxa (dabigatran), Minivelle (estradiol transdermal patch), Zometa (zoledronic acid infusion), Reclast (zoledronic acid infusion), Daytrana (methylphenidate transdermal patch), Velcade (bortezomib), Uloric (febuxostat), Lexiva (fosamprenavir), Actoplus Met XR (pioglitazone/metformin), Celebrex (celecoxib), and Nuvigil (armodafinil).
  • Represented Azurity Pharmaceuticals in patent litigations relating to Azurity’s Nymalize product.
  • Represented Edwards Lifesciences in patent infringement litigation involving mitral and aortic valve holders and intra-aortic filters.
  • Represented LSI at the International Trade Commission against twenty-three respondents relating to semiconductor integrated circuits.
  • Represented,, and Alexa Internet against claims that search engine capabilities rendered them liable for copyright infringement.
  • Represented Area 55 in patent litigation involving wine aeration.
  • Represented MEEI in patent infringement dispute involving treatment of age-related macular degeneration.
  • Represented Praxair in patent litigation involving gas delivery systems for semiconductor fabrication.